Eli M Roth

Summary

Publications

  1. doi request reprint ω-3 carboxylic acids for hypertriglyceridemia
    Eli M Roth
    Cardiology University of Cincinnati, Sterling Research Group, 375 Glensprings Dr 2nd Floor, Cincinnati, OH 45246 USA 1 513 671 8080 1 513 671 8090
    Expert Opin Pharmacother 16:123-33. 2015
  2. doi request reprint Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial
    Eli M Roth
    The Sterling Research Group, Cincinnati, OH, USA Electronic address
    Int J Cardiol 176:55-61. 2014
  3. pmc Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Hypertens (Greenwich) 15:584-92. 2013
  4. doi request reprint Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Lipidol 6:534-44. 2012
  5. doi request reprint Fish oil for primary and secondary prevention of coronary heart disease
    Eli M Roth
    Division of Cardiovascular Diseases, University of Cincinnati College of Medicine and Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Curr Atheroscler Rep 12:66-72. 2010
  6. doi request reprint Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
    Eli M Roth
    Sterling Research Group, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:175-86. 2010
  7. doi request reprint Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
    Eli M Roth
    Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Cardiovasc Drugs Ther 24:421-8. 2010
  8. doi request reprint Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
    Eli M Roth
    Sterling Research Group, University of Cincinnati, Cincinnati, Ohio, USA
    J Cardiovasc Pharmacol 54:196-203. 2009
  9. doi request reprint Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    Eli M Roth
    Sterling Research Group, Cincinnati, OH, USA
    N Engl J Med 367:1891-900. 2012
  10. pmc Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Eur Heart J 31:480-8. 2010

Detail Information

Publications12

  1. doi request reprint ω-3 carboxylic acids for hypertriglyceridemia
    Eli M Roth
    Cardiology University of Cincinnati, Sterling Research Group, 375 Glensprings Dr 2nd Floor, Cincinnati, OH 45246 USA 1 513 671 8080 1 513 671 8090
    Expert Opin Pharmacother 16:123-33. 2015
    ..The FFA form of EPA and DHA is associated with higher bioavailability than other forms of ω3 fatty acids, potentially resulting in efficacy at lower doses and less dependence on meal relationship...
  2. doi request reprint Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial
    Eli M Roth
    The Sterling Research Group, Cincinnati, OH, USA Electronic address
    Int J Cardiol 176:55-61. 2014
    ..Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy...
  3. pmc Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Hypertens (Greenwich) 15:584-92. 2013
    ..005]) at week 12. SeBP reduction and goal attainment (≥30 kg/m(2) , 63%; <30 kg/m(2) , 67%) was maintained through week 52/early termination. Triple-combination treatment was well tolerated in both BMI subgroups. ..
  4. doi request reprint Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies
    Eli M Roth
    Sterling Research Group, Cincinnati, OH 45219, USA
    J Clin Lipidol 6:534-44. 2012
    ..These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels...
  5. doi request reprint Fish oil for primary and secondary prevention of coronary heart disease
    Eli M Roth
    Division of Cardiovascular Diseases, University of Cincinnati College of Medicine and Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Curr Atheroscler Rep 12:66-72. 2010
    ..These data have led to specific recommendations for use of omega-3 fatty acids in several cardiovascular areas...
  6. doi request reprint Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study
    Eli M Roth
    Sterling Research Group, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:175-86. 2010
    ....
  7. doi request reprint Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study
    Eli M Roth
    Sterling Research Group, 2230 Auburn Avenue, Cincinnati, OH 45219, USA
    Cardiovasc Drugs Ther 24:421-8. 2010
    ..This phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of rosuvastatin 5 mg coadministered with fenofibric acid 135 mg in patients with mixed dyslipidemia...
  8. doi request reprint Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects
    Eli M Roth
    Sterling Research Group, University of Cincinnati, Cincinnati, Ohio, USA
    J Cardiovasc Pharmacol 54:196-203. 2009
    ..Given that some patients may not achieve optimal TG levels with a single agent, we hypothesized that concomitant use of P-OM3 or addition of P-OM3 to FENO would result in a TG reduction greater than that with FENO alone...
  9. doi request reprint Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    Eli M Roth
    Sterling Research Group, Cincinnati, OH, USA
    N Engl J Med 367:1891-900. 2012
    ..REGN727/SAR236553 (designated here as SAR236553), a fully human PCSK9 monoclonal antibody, increases the recycling of LDL receptors and reduces LDL cholesterol levels...
  10. pmc Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Eur Heart J 31:480-8. 2010
    ....
  11. doi request reprint Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
    Evan A Stein
    Metabolic and Atherosclerosis Research Centre, Cincinnati, OH, USA
    Eur Heart J 35:2249-59. 2014
    ..We report a pooled analysis from four phase 2 studies of evolocumab (AMG 145), a monoclonal antibody to PCSK9...
  12. doi request reprint ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks
    Eli M Roth
    University of Cincinnati and Sterling Research Group, 375 Glensprings Drive, 2nd Floor, Cincinnati, OH 45246, USA
    Future Cardiol 11:27-37. 2015
    ..2% (least square [LS] mean) reduction in LDL-cholesterol compared with a 15.6% (LS mean) reduction with ezetimibe (LS mean difference of 31.6%; p < 0.0001). Safety parameters and adverse events were similar between the two groups. ..